Anti-TNFα Agents May Increase Risk for Crohn Disease, Ulcerative Colitis
Treatment with anti-TNFα agents for conditions other than inflammatory bowel disease may increase the risk of developing Crohn disease or ulcerative colitis.
Crohn Disease
IBD Treatments Compared in Older Patients With Crohn Disease, Ulcerative Colitis
In older patients with inflammatory bowel disease, tumor necrosis factor alpha antagonist therapy and vedolizumab were found to be comparable with regard to both safety and effectiveness.
Biosimilar Infliximab CT-P13 Similar to Reference Infliximab for Crohn Disease
Patients with Crohn disease were enrolled in a comparative cohort study that analyzed the outcomes of reference product infliximab vs biosimilar treatment.
Oral contraceptives increase surgery risk for women with Crohn disease
Women with Crohn disease who use oral contraceptives for more than 1 year have an increased risk of surgery.
FDA approves Inflectra biosimilar for rheumatoid arthritis, psoriasis
The biosimilar has also been approved for Crohn’s disease, ulcerative colitis, and ankylosing spondylitis.
Benefit of fiber intake not equal in IBD patients
Patients with Crohn disease who ate high-fiber foods were 40% less likely to have a disease flare.
Crohn disease: diagnosis and treatment
A condition prone to recurrence, Crohn disease has a complicated presentation and pathophysiology, but multiple treatment options are available.
Non-TNF blocker for colitis, Crohn disease
Entyvio can be used to treat ulcerative colitis and Crohn disease in adults who did not have success with other treatments.
Asthma, COPD linked with more inflammatory bowel disease
People with airway diseases are more likely to have inflammatory bowel disease.
Vedolizumab approved to treat ulcerative colitis, Crohn disease
The FDA has approved vedolizumab for patients with inadequate response to conventional therapies.
Next post in Web Exclusives
